{
    "clinical_study": {
        "@rank": "144574", 
        "arm_group": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan\u00ae UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The study will evaluate patients diagnosed with primary open angle glaucoma or ocular\n      hypertension who are switched to Lumigan\u00ae UD monotherapy for medical reasons in accordance\n      with physician standard clinical practice.  All treatment decisions lie with the physician."
        }, 
        "brief_title": "A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan\u00ae UD Monotherapy for Medical Reasons", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma, Primary Open Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with primary open-angle glaucoma or ocular hypertension\n\n          -  Previously prescribed intraocular pressure (IOP)-lowering medication with\n             insufficient IOP control and is now being switched to Lumigan\u00ae UD for medical reasons\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with primary open-angle glaucoma or ocular hypertension"
            }
        }, 
        "enrollment": {
            "#text": "1834", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853085", 
            "org_study_id": "MAF/AGN/OPH/GLA/038"
        }, 
        "intervention": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan\u00ae UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.", 
            "intervention_name": "Bimatoprost Ophthalmic Solution", 
            "intervention_type": "Drug", 
            "other_name": "Lumigan\u00ae UD"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wiesloch", 
                    "country": "Germany", 
                    "state": "Baden-W\u00fcrttemberg"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853085"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Physician Assessment of IOP-Lowering Effect on a 3-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Patient Assessment of Tolerability on a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Tolerability on a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients who Discontinue Treatment", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients Prescribed by the Physician to Continue Treatment", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}